Company: PRGO
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001585364-25-000056
Chunk: 139

Company: PERRIGO Co plc
Filing Date: 2025-05-07
Form: 10-Q
Item: Part II, Item 1
Chunk 139
---
 $11.4 million in the Upper Respiratory and Pain and Sleep-Aids categories, due primarily to higher incidence levels of cough cold compared to the prior year period and improved supply of key products, as well as higher net sales of $4.9 million in the Healthy Lifestyle category led by strong momentum in smoking cessation brand NiQuitin®, and $2.7 million from the Skin Care category led by brands Compeed® and Sebamed®, and earlier customer purchases ahead of the spring/summer season compared to the prior year period.

43

Perrigo Company plc - Item 2CSCI

CSCI net sales by product category were as follows:

SalesThree Months Ended(in millions, except percentages)March 29, 2025March 30, 2024$ Change% ChangeSkin Care$111.5 $114.7 $(3.2)(2.8)%Upper Respiratory73.5 69.1 4.4 6.4 %Healthy Lifestyle66.6 64.6 2.0 3.1 %Pain and Sleep-Aids53.6 51.4 2.2 4.3 %VMS37.7 44.6 (6.9)(15.5)%Women's Health32.4 32.0 0.4 1.3 %Oral Care22.5 28.7 (6.2)(21.6)%Digestive Health9.6 9.5 0.1 1.1 %Other CSCI15.9 23.3 (7.4)(31.8)%Total CSCI$423.1 $437.9 $(14.8)(3.4)%

Sales in each category were driven primarily by: 

•Skin Care: Net sales of $111.5 million decreased 2.8%, inclusive of a 3.4% unfavorable effect of currency translation, including the impact of -1.8% from divested businesses and exited product lines. Growth was led by brands Compeed® and Sebamed®, and earlier customer purchases ahead of the spring/summer season compared to the prior year.  

•Upper Respiratory: Net sales of $73.5 million increased 6.4%, inclusive of a 2.7% unfavorable effect of currency translation, due primarily to higher cough cold seasonal sell-in activities, improved supply of a key product and slightly